摘要
目的 以P53/人B细胞淋巴瘤-xL(Bcl-xL)信号通路为基础,探讨白藜芦醇对人胃癌MKN-45细胞凋亡的影响。方法 体外培养胃癌MKN-45细胞,以不同浓度的白藜芦醇(5、10、20、40、80μg·mL^(-1))分别干预细胞24、48、72 h,采用细胞增殖实验检测细胞增殖情况。设空白组和白藜芦醇高、中、低剂量组(30、20、10μg·mL^(-1)),干预MKN-45细胞48 h, DAPI染色观察细胞核的形态;采用流式细胞仪检测细胞的凋亡情况;蛋白免疫印迹法检测细胞中P53、Bcl-xL蛋白的表达;实时荧光定量聚合酶链式反应检测细胞中P53、Bcl-xL mRNA的表达。结果 随着白藜芦醇浓度的增加,能明显抑制胃癌MKN-45细胞增殖;与空白组比较,白藜芦醇中、高剂量组细胞的细胞核逐渐皱缩,甚至破裂;两组细胞的凋亡率明显增加,P53的表达均增加,Bcl-xL的表达均降低。结论 白藜芦醇可激活MKN-45细胞中P53/Bcl-xL信号通路,增加P53的表达,降低Bcl-xL的表达,从而诱导MKN-45细胞凋亡。
OBJECTIVE To explore the effect of resveratrol on the apoptosis of human gastric cancer MKN-45 cells based on P53/Bcl-xL signaling pathway.METHODS Gastric cancer MKN-45 cells were cultured in vitro.Different concentrations of resveratrol(5,10,20,40,80 μg·mL^(-1))interfered with the cells for 24,48 and 72 h, and the cell proliferation test(CCK-8) method was used to detect cell proliferation.Control group and high-, medium-, and low-dose resveratrol groups(30,20,10 μg·mL^(-1)) were set, intervening in MKN-45 cells for 48 h.DAPI staining was used to observe the nucleus morphology, flow cytometry to detect apoptosis, Western blot to detect P53 and Bcl-xL protein expression in cells, and qRT-PCR to detect P53 and Bcl-xL mRNA expression in cells.RESULTS With the increase of resveratrol concentration, it could significantly inhibit the proliferation of gastric cancer MKN-45 cells.Compared with the control group, the cell nucleus of the medium-and high-dose groups of resveratrol gradually shrank and even ruptured.The apoptosis rate of the the medium-and high-dose groups increased significantly;the expression of P53 in the the medium-and high-dose groups of resveratrol increased;and the expression of Bcl-xL decreased.CONCLUSION Resveratrol can activate the P53/Bcl-xL signaling pathway in MKN-45 cells, increase the expression of P53, and reduce the expression of Bcl-xL, thereby inducing apoptosis of MKN-45 cells.
作者
杨小蒨
任翠翠
唐锐
曹睿琳
孙苗
刘子源
窦建卫
YANG Xiaoqian;REN Cuicui;TANG Rui;CAO Ruilin;SUN Miao;LIU Ziyuan;DOU Jianwei(School of Pharmacy,Xi'an Jiaotong University,Xi'an,Shaanxi,710061 P.R.China;Xi'an No.1 Hospital,Xi'an,Shaanxi,710002 P.R.China;Central Hospital of Xianyang,Xianyang,Shaanxi,712000 P.R.China)
出处
《华西药学杂志》
CAS
CSCD
2022年第5期507-510,共4页
West China Journal of Pharmaceutical Sciences
基金
陕西省重点研发计划(2019SF-304
2019SF-013)。